10x Genomics, Inc.
HealthcareNASDAQ:TXG · NASDAQ Global Select
-$0.21 today
Vol 2.01M · Avg 2.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-5.5%
avg -11.8%
ROIC
-12.3%
avg -28.3%
ROA
-4.2%
avg -27.9%
Analysis
ROA is currently the strongest return metric at -4.2% versus its period average of -27.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Serge Saxonov | Co-Founder, Chief Executive Officer & Director | $1.31M | — | 49 | $1.14M | 0.90% |
Benjamin J. Hindson | Co-Founder, President, Chief Scientific Officer & Director | $811,604.00 | — | 51 | $502,000.00 | 0.40% |
Adam S. Taich | Chief Financial Officer, Treasurer, Principal Financial Officer & Principal Accounting Officer | $792,041.00 | — | 51 | $379,898.00 | 0.30% |
Mennah Moustafa | Chief Commercial Officer | $390,782.00 | — | — | — | — |
Randy Wu | General Counsel and Secretary | — | — | — | — | — |
Jens Durruthy | Associate Director of Product Management | — | — | — | — | — |
Jim Goodrich | Chief of Global Operations | — | — | — | — | — |
Michael Schnall-Levin | Founding Scientist & Chief Technology Officer | — | — | — | — | — |
Cassie Corneau | Manager of Investor Relations & Strategic Finance | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
19
$3.95M
Net Sentiment
$3.95M
Net selling
Most Active
Saxonov Serge
10 transactions
1–10 of 19
Analysis
Insiders reported 0 buys worth $0.00 and 19 sells worth $3.95M over the last 12 months. That adds up to net selling of $3.95M. Saxonov Serge was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +49.7% | +6.7% (9yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +49.7% over three years. Forward estimates point to Revenue at +6.7% (9yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Guardian Pharmacy Services, Inc.
NYSE:GRDN
$2.73B
Progyny, Inc.
NASDAQ:PGNY
$2.09B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
Teladoc Health, Inc.
NYSE:TDOC
$1.32B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Omada Health
NASDAQ:OMDA
$1.02B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Certara, Inc.
NASDAQ:CERT
$808.94M
Who manages TXG?
10x Genomics, Inc. (TXG) lists 9 active executives. The top listed executive is Serge Saxonov, Co-Founder, Chief Executive Officer & Director.
Are TXG insiders buying or selling?
Recent insider activity shows net selling of $6.37M.
Explore More
Continue the stock analysis
Jump to another research area for this company.